Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$7.45 USD
+0.21 (2.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $7.45 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMRX 7.45 +0.21(2.90%)
Will AMRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMRX
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
AMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Other News for AMRX
Amneal to Report Second Quarter 2024 Results on August 9, 2024
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Alector (ALEC)
Piper Sandler Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)